Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $595.91M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 0.88M
Average 1.07M
IMMX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Immix Biopharma, Inc.NASDAQ: IMMX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $5.98M rose 202.8% year over year, ahead of the +102.3% change in trailing-twelve-month research & development. Sequentially, it rose 4.4% from the prior quarter. Over 3 fiscal years it compounded at +57.1% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +202.8% holds above the trailing-twelve-month pace of +102.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 16.26M USD
- Year-over-year change
- +44.0%
- 4-year CAGR
- +236.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.26M | +44.0% |
| FY2024 | 2024-12-31 | 11.29M | +29.3% |
| FY2023 | 2023-12-31 | 8.74M | +108.2% |
| FY2022 | 2022-12-31 | 4.2M | +3216.1% |
| FY2021 | 2021-12-31 | 126.53K | — |
Research & Development vs competitors
How IMMX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +102.3% is the highest of 11, against a peer median of +3.2%.
- Over three fiscal years its annual growth of +57.1% compares with a peer median of +13.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $497M USD | +2.5% | +22.0% | 424.8% | |
| LTM Aug 2026 | $331.95M USD | +10.2% | +18.6% | 47.3% | |
| LTM Sep 2026 | $283.32M USD | +31.2% | +43.9% | 252960.7% | |
| FY2025 | €177.76M EUR | +21.3% | +54.4% | — | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $86.08M USD | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $69.1M USD | -13.8% | -14.9% | 194.4% | |
| FY2025 | A$61.41M AUD | +47.8% | +25.1% | 1217.6% | |
| LTM Mar 2026 | $31.62M USD | -19.6% | +9.2% | 6022.3% | |
| LTM Mar 2026 | $20.26M USD | +102.3% | +57.1% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.28M CNY | -94.8% | -61.3% | — |
| Peer median (excluding IMMX) | — | +3.2% | +13.9% | 424.8% | |
Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 364.5K |
| Gross Profit | 0 | 0 | 0 | 0 | (364.5K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 126.53K | 4.2M | 8.74M | 11.29M | 16.26M |
| Selling, General & Admin | 1.23M | 4.02M | 7.41M | 11.38M | 13.7M |
| Operating Expenses | 1.35M | 8.22M | 16.14M | 22.67M | 26.85M |
| Depreciation & Amortization | 2.47K | 2.14K | 5.47K | 115.39K | 364.5K |
| EBITDA | (24.2M) | (8.22M) | (15.56M) | (21.54M) | (29.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.35M) | (8.22M) | (16.14M) | (22.67M) | (27.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 572.01K | 1.02M | 555.53K |
| Interest Expense | 179.85K | 497 | 0 | 0 | 0 |
| Other Income / Expenses | (23.03M) | (497) | 572.01K | 1.02M | (2.19M) |
| Income Before Tax | (24.38M) | (8.22M) | (15.57M) | (21.66M) | (29.4M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 6.01K | 10.27K | 26.42K | 41.04K | 37.72K |
| Net Income | (24.38M) | (8.23M) | (15.43M) | (21.61M) | (29.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| EPS (Diluted) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| Weighted Avg Shares | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M |
| Weighted Avg Shares (Diluted) | 3.67M | 13.89M | 17.34M | 28.29M | 32.97M |
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.